logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
X

Xinan Sheng

Peking University Cancer Hospital and Institute
H指数:41
被引数:6,721

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma

帕博利珠单抗联合仑伐替尼治疗黏膜黑色素瘤的II期围手术期研究

Nature Communications
IF15.7
2026-05-160
OAAI
Lili Mao; Yumei Lai; Hong Zheng; Ming Cui; Lifeng Li; Ziyi Liu; Hongyu Zhou; Linzi Sun; Caili Li; Xiaoting Wei; Junjie Gu; Xue Bai; Yan Kong; Chuanliang Cui; Zhihong Chi; Xinan Sheng; Bin Lian; Siming Li; Xieqiao Yan; Bixia Tang; Juan Li; Li Zhou; Xuan Wang; Jun Guo; Jie Dai; Lu Si
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

Disitamab vedotin联合toripalimab在HER2表达型晚期尿路上皮癌中的应用

NEW ENGLAND JOURNAL OF MEDICINE
IF78.5
2025-10-016
PRE
Sheng, Xinan; Zeng, Gongqian; Zhang, Cuijian; Zhang, Qingyun; Bian, Jiasheng; Niu, Haitao; Li, Jun; Shi, Yanxia; Yao, Kai; Hu, Bin; Liu, Ziling; Liao, Hong; Yu, Zhixian; Jin, Baiye; Zhao, Peng; Yang, Tiejun; Liu, Xianling; Qin, Yang; Xue, Xueyi; Gou, Xin; Huang, Jian; Gu, Jiang; Qi, Xiaolong; Zhang, Lu; Ma, Guoxian; Liu, Beisong; Fang, Jianmin; Jiang, Shusuan; He, Zhisong; Zhou, Aiping; Guo, Jun
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial

一线贝美替尼联合阿尼洛替尼与舒尼替尼对比治疗晚期肾细胞癌（ETER100）：一项多中心、随机、开放标签、III期临床试验

lancet oncology
IF0
2025-09-010
PRE
Aiping Zhou; Pengfei Shen; Juan Li; Wang Qu; Zengjun Wang; Xiubao Ren; Yuan Li; Shusuan Jiang; Gang Li; Yu Zeng; Weijun Qin; Jin Wu; Peng Chen; Fangjian Zhou; Hongqian Guo; Zhigang Ji; Yongquan Wang; Zhisong He; Jitao Wu; Benkang Shi; Lian Liu; Xudong Yao; Lulin Ma; Ziling Liu; Xin Gou; Bin Fu; Shaogang Wang; Kui Jiang; Tie Chong; Xinhua Tu; Xu Zhang; Dexin Yu; Mulati Rexiati; Xueyi Xue; Jing Fei; Jianghou Wan; Liqun Jia; Yi He; Tongjian Cui; An-Qi Yang; Jun Guo; Xinan Sheng
Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study

DV在HER2阴性及HER2低表达局部晚期或转移性尿路上皮癌中的有效性与安全性：一项II期研究的结果

Med
IF11.8
2025-03-190
PRE
Xieqiao Yan; Juan Li; Huayan Xu; Yiqiang Liu; Li Zhou; Siming Li; Xiaowen Wu; Bixia Tang; Zhihong Chi; Chuanliang Cui; Lu Si; Lili Mao; Bin Lian; Xuan Wang; Rong Duan; Caili Li; Jianmin Fang; Jun Guo; Xinan Sheng
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study

Disitamab vedotin联合toripalimab治疗局部晚期或转移性尿路上皮癌 (RC48-C014): Ib/II期剂量递增和剂量扩展研究

ANNALS OF ONCOLOGY
IF65.4
2025-03-014
PRE
Zhou, L.; Yang, K. W.; Zhang, S.; Yan, X. Q.; Li, S. M.; Xu, H. Y.; Li, J.; Liu, Y. Q.; Tang, B. X.; Chi, Z. H.; Si, L.; Cui, C. L.; Guo, H. Q.; He, Z. S.; Guo, J.; Sheng, X.
Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma
CLINICAL CANCER RESEARCH
IF10.2
2024-03-211
OAAI
Chen, Junru; Hu, Xu; Zhao, Junjie; Yin, Xiaoxue; Zheng, Linmao; Guo, Jingjing; Chen, Jianhui; Wang, Yongquan; Sheng, Xinan; Dong, Haiying; Liu, Xiaodong; Zhang, Xingming; Liang, Jiayu; Liu, Haolin; Yao, Jin; Liu, Jiyan; Shen, Yali; Chen, Zhibin; He, Zhengyu; Wang, Yaodong; Chen, Ni; Nie, Ling; Zhang, Mengni; Pan, Xiuyi; Chen, Yuntian; Liu, Haoyang; Zhang, Yaowen; Tang, Yanfeng; Zhu, Sha; Zhao, Jinge; Dai, Jindong; Wang, Zilin; Zeng, Yuhao; Wang, Zhipeng; Huang, Haojie; Liu, Zhenhua; Shen, Pengfei; Zeng, Hao; Sun, Guangxi
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
ANNALS OF ONCOLOGY
IF65.4
2024-02-0139
OA
Yan, X. Q.; Yey, M. J.; Zou, Q.; Chen, P.; He, Z. S.; Wu, B.; He, D. L.; He, C. H.; Xue, X. Y.; Ji, Z. G.; Chen, H.; Zhang, S.; Liu, Y. P.; Zhang, X. D.; Fu, C.; Xu, D. F.; Qiu, M. X.; Lv, J. J.; Huang, J.; Ren, X. B.; Cheng, Y.; Qin, W. J.; Zhang, X.; Zhou, F. J.; Ma, L. L.; Guo, J. M.; Ding, D. G.; Wei, S. Z.; He, Y.; Guo, H. Q.; Shi, B. K.; Liu, L.; Liu, F.; Hu, Z. Q.; Jin, X. M.; Yang, L.; Zhu, S. X.; Liu, J. H.; Huang, Y. H.; Xu, T.; Liu, B.; Sun, T.; Wang, Z. J.; Jiang, H. W.; Yu, D. X.; Zhou, A. P.; Jiang, J.; Luan, G. D.; Jin, C. L.; Xu, J.; Hu, J. X.; Huang, Y. R.; Guo, J.; Zhai, W.; Sheng, X. N.
RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomized, open-label, phase III study

RENOTORCH: Toripalimab联合阿西替尼与舒尼替尼在晚期肾细胞癌 (RCC) 一线治疗中的比较-一项随机，开放标签，III期研究

ANNALS OF ONCOLOGY
IF65.4
2023-10-012
PRE
Sheng, X.; Ye, M.; Zou, Q.; Chen, P.; He, Z.; Wu, B.; He, D.; He, C.; Xue, X.; Ji, Z.; Chen, H.; Zhang, S.; Liu, Y.; Zhai, W.; Zhang, X.; Fu, C.; Xu, D.; Qiu, M.; Huang, Y.; Guo, J.

研究方向

暂未获取到该数据
L
Lu Si
H 指数:45论文数:593被引数:8,924
C
Chuanliang Cui
H 指数:38论文数:296被引数:6,279
Z
Zhihong Chi
H 指数:42论文数:323被引数:6,808
J
Jun Guo
H 指数:45论文数:399被引数:9,483
Y
Yan Kong
H 指数:43论文数:319被引数:5,803
X
Xieqiao Yan
H 指数:26论文数:187被引数:2,527
J
Jie Dai
H 指数:32论文数:176被引数:3,239
L
Lili Mao
H 指数:33论文数:238被引数:4,101
B
Bin Lian
H 指数:32论文数:238被引数:3,594
L
Li Zhou
H 指数:26论文数:174被引数:2,590